Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.

Huang R, Feng Y, Wang Y, Qin X, Melgiri ND, Sun Y, Li X.

PLoS One. 2017 Jan 3;12(1):e0168582. doi: 10.1371/journal.pone.0168582. eCollection 2017.

2.

Comparison of the Efficacy and Safety of Different ACE Inhibitors in Patients With Chronic Heart Failure: A PRISMA-Compliant Network Meta-Analysis.

Sun W, Zhang H, Guo J, Zhang X, Zhang L, Li C, Zhang L.

Medicine (Baltimore). 2016 Feb;95(6):e2554. doi: 10.1097/MD.0000000000002554.

3.

Treatment of hypertension in peripheral arterial disease.

Lane DA, Lip GY.

Cochrane Database Syst Rev. 2013 Dec 4;(12):CD003075. doi: 10.1002/14651858.CD003075.pub3. Review.

PMID:
24307487
4.

Evidence-based hypertension treatment in patients with diabetes.

Garcia-Touza M, Sowers JR.

J Clin Hypertens (Greenwich). 2012 Feb;14(2):97-102. doi: 10.1111/j.1751-7176.2011.00570.x. Epub 2011 Dec 19. Review.

5.

Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials.

Zou Z, Xu FY, Wang L, An MM, Zhang H, Shi XY.

J Hum Hypertens. 2011 Mar;25(3):203-10. doi: 10.1038/jhh.2010.60. Epub 2010 Jun 10.

PMID:
20535140
6.

Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited.

Knütter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M.

J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19.

7.

[Antiatherogenic effects of angiotensin converting enzyme inhibitors from the point of view of evidence based medicine].

Preobrazhenskiĭ DV, Batyraliev TA, Peresypko MK, Pershukov IV, Sidorenko BA.

Kardiologiia. 2007;47(5):73-86. Review. Russian.

PMID:
18260863
8.

Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure.

Baguet JP, Legallicier B, Auquier P, Robitail S.

Clin Drug Investig. 2007;27(11):735-53.

PMID:
17914893
9.

Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?

Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ.

Ann Intern Med. 2006 Jun 20;144(12):884-93.

PMID:
16785477
11.

The impact of suppressing the renin-angiotensin system on atrial fibrillation.

Kalus JS, Coleman CI, White CM.

J Clin Pharmacol. 2006 Jan;46(1):21-8.

PMID:
16397280
12.

Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.

McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Piña IL, Soler-Soler J, Swedberg K.

Eur J Heart Fail. 2005 Aug;7(5):710-21.

13.

Trandolapril did not reduce cardiovascular death or other events in stable coronary artery disease.

Granger CB.

ACP J Club. 2005 May-Jun;142(3):66. No abstract available.

PMID:
15862065
14.

Trandolapril delayed persistent microalbuminuria in hypertension, type 2 diabetes, and normoalbuminuria.

Kudva Y, Hunt D.

ACP J Club. 2005 May-Jun;142(3):65. No abstract available.

PMID:
15862064
15.

Angiotensin II and trials of cardiovascular outcomes.

Sleight P.

Am J Cardiol. 2002 Jan 24;89(2A):11A-16A; discussion 16A-17A.

PMID:
11835905
16.
17.

Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists.

Zannad F, Matzinger A, Larché J.

Am J Hypertens. 1996 Jul;9(7):633-43. Erratum in: Am J Hypertens 1997 Apr;10(4 Pt 1):482.

PMID:
8806975

Supplemental Content

Loading ...
Support Center